1. Date of preparation April 2014 BRI001081ACC.14Annual ScientificSessions of theAmerican College ofCardiologyWashington DC29-31 March 2014

2. Date of preparation April 2014 BRI001081Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedACC.14, compiled by an external medical writer and sponsored by AstraZeneca. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights. 3. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Acute decompensated heart failureCommentary:Associate Professor John AthertonRoyal Brisbane and Womens Hospital 4. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 5. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 6. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 7. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 8. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Seralaxin (recombinant relaxin) in ADHF:RELAX-AHF study 9. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 10. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 11. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 12. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Relaxin vs nitrate vs nesiritide 13. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 14. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 15. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Furosemide:Bolus vs infusion, low dose vs high dose 16. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Furosemide:Bolus vs infusion, low dose vs high dose 17. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Furosemide: Low dose vs high dose 18. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Furosemide: Low dose vs high dose 19. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 20. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014New inotropes: Istaroxime 21. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 22. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014New inotropes: Stresscopin 23. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 24. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014New inotropes: CXL-1020 25. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 26. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014New inotropes: Myosin activators 27. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 28. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Omecamtiv mecarbil: ATOMIC-AHF trial 29. Commentary: Associate Professor John AthertonDate of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 Vasodilators continue to have key role in the management of acutedecompensated heart failure, but there is a need to update theevidence base for older agents. Seralaxin is a promising new vasodilator that improved symptoms andprovided a significant mortality benefit in the RELAX-AHF study, with afurther study underway, powered for cardiovascular mortality . Recent evidence supports an assertive approach to decongestion. Therisks of associated renal failure may have been overstated. Although the efficacy of novel inotropes has often been disappointing, anumber of newer agents are in the advanced stages of developmentand show some promise.